Une nouvelle classe de médicaments synthétiques.

Un autre médicament de cette classe de médicament synthétiques :

(Jun. 3, 2008) — Men with a certain type of prostate cancer have been shown to respond to a new chemotherapy drug, Sagopilone, plus prednisone in an international trial led by Oregon Health & Science University Cancer Institute researchers.

Les hommes avec un certain type de cancer de la prostate ont montré une réponse à un nouveua médicament, le sagopilone, avec la prednisone dans un essai international conduite par le centre de l'orégon.

The research involved men with androgen-independent prostate cancer that has metastasized, meaning their cancer has spread beyond the prostate and is not longer responding to hormonal therapies. This is the most advanced form of prostate cancer. Prostate cancer is the most common type of cancer in men in the United States, where it is responsible for more male deaths than any other cancer, except lung cancer.

Cette recherche implique des hommes avec le cancer avancé de la prostate qui ne réponds plus aux traitements anti-hormonal.

"We are showing solid activity that this drug shows promise," said Tomasz Beer, M.D., principal investigator. He is the Grover C. Bagby Endowed Chair for Cancer Research, director of the Prostate Cancer Research Program at the OHSU Cancer Institute and associate professor of medicine (hematology/medical oncology), OHSU School of Medicine.

This research will be presented Saturday, May 31 at 8 a.m. at the annual American Association of Clinical Oncology in Chicago.

Of the 37 study participants taking the Sagopilone and prednisone long enough to be evaluated, the majority showed positive results in the reduction of their prostate specific antigens, or PSA. PSA is often elevated in the presence of prostate cancer.

Des 37 participants qui ont pris la Sagopilone avec la prednisone assez longtemps pour être évalué, la majorité ont montré des résultats positifs dans la réduction des antigènes spécifiques PSA.

During the three-month trial thirteen study participants had a more than 50 percent reduction in their PSA; 23 showed a 30 percent reduction; one who had radiographic measurable disease showed complete response; and four had unconfirmed prostate response. A 30 percent reduction in PSA levels in three months is a strong indicator of survival.

durant les 3 mois de l'essai , 13 particpants ont montré une réduction du psa de plus de 50%, 23 ont montré une réduction de 30%, 1 qui avait une maladie décernable sur radiographie a montré une réponse complète et 4 ont eu une réponse non confirmée. Une réduction de 30% du psa en 3 mois est un fort indicateur de survie.

Sagopilone, a fully synthetic derivation, is a new class of drug that inhibits growth and the spread of malignant cell, similar to docetaxel, which has been the gold standard for this type of hormone independent prostate cancer. Docetaxel, however, it is not a cure and not all patients benefit from it. For this reason, Beer and colleagues are committed to searching for new drugs that will be effective against advanced prostate cancer.

LA sagopilone est un médicament 100% synthétique.

"We look forward to completing this study and to the further investigation of Sagopilone as a new treatment option for men with advanced prostate cancer," said Beer.

The study was carried out in collaboration with members of the Prostate Cancer Clinical Trials Consortium, as well as a number of collaborating institutions in the United States and Argentina.

(Jun. 4, 2008) — Synthetic molecules designed by two Hebrew University of Jerusalem researchers have succeeded in reducing and even eliminating the growth of human malignant tissues in mice, while having no toxic effects on normal tissue.

Des molécules synthétiques concues par deux chercheurs hébreux de Jérusalem ont réussi à réduire et même éliminer la croissance de tissus cancéreux chez la souris et n'ont eu que très peu d'effets toxiques.

The molecules developed by Dr. Arie Dagan and Prof. Shimon Gatt of the Department of Biochemistry of the Hebrew University-Hadassah Medical School affected the metabolism of various sphingolipids and consequently those of cancer cells. Sphingolipids are a family of complex lipid molecules that are involved in signaling pathways that mediate cell growth, differentiation and death.

Les molécules développées par le docteur Dagan et Gatt affectent le métabolisme du sphingolipide et conséquemment celui de la cellule cancéreuses. Les sphingolipides sont une famille de molécules complexe qui sont impliquées dans les chemins cellulaires qui gèrent la croissance, la différétiation et la mort.

Several of the most active molecules developed by Dagan and Gatt are derivatives of ceramide (a member of the sphingolipid family). Ceramide induces programmed cell death (apoptosis) in a variety of cancer cells.

Plusieurs des plus actives de ces cellules développées par Dagna et Gatt sont dérivées de la ceramide.

The natural levels of ceramide in cancer cells are generally too low to induce a therapeutic effect. In preclinical studies to date, various treatments with the synthetic molecules resulted in an elevation of ceramide levels in cancer cells, thereby leading to their death by apoptosis. In addition, these synthetic molecules appear to be synergistic with chemotherapeutic drugs.

Dagan and Gatt state that their studies demonstrated that their synthetic compounds reduced considerably the sizes of pancreatic, prostate and breast tumors with little or no effects on normal cells and tissues. The researchers see this as a precursor to the development of a new generation of anti-cancer drugs that induce, selectively, apoptosis only to tumorous cells. These drugs are expected to be highly effective while inducing fewer side effects than current anti-cancer drugs.

Les chercheurs duisent que leurs études démontreent que les molécules synthétiques réduisent considérablement la taille des tumeurs du de la et celles du sans affecter les tissus normaux. Ces médicaments sont précurseurs d'une nouvelle classe de médicaments anti-cancer qui induieront lA'poptose sélectivement sur les cellules cancéreuses. On s'attends à ce que ces médicaments soient hautement eficace sans d'effets secondaires.

Prof. Shimon Gatt and Dr. Arie Dagan's development of synthetic sphingolipid analogs as anti-cancer drugs is patented by Yissum, the technology transfer company of the Hebrew University of Jerusalem. Yissum licensed the technology to BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange,, for the development of these synthetic molecules as anti-cancer drugs.